ES2156843T3 - Prediccion de la enfermedad arterial coronaria. - Google Patents

Prediccion de la enfermedad arterial coronaria. Download PDF

Info

Publication number
ES2156843T3
ES2156843T3 ES98910298T ES98910298T ES2156843T3 ES 2156843 T3 ES2156843 T3 ES 2156843T3 ES 98910298 T ES98910298 T ES 98910298T ES 98910298 T ES98910298 T ES 98910298T ES 2156843 T3 ES2156843 T3 ES 2156843T3
Authority
ES
Spain
Prior art keywords
allele
disease
coronary artery
artery disease
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98910298T
Other languages
English (en)
Spanish (es)
Other versions
ES2156843T1 (es
Inventor
Sheila E. Clin. Sci. Cnt. No. Gen Hosp. Francis
David C. Clin. Sci. Cnt. No. Gen. Hosp Crossman
Gordon W. Duff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interleukin Genetics Inc
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of ES2156843T1 publication Critical patent/ES2156843T1/es
Application granted granted Critical
Publication of ES2156843T3 publication Critical patent/ES2156843T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES98910298T 1997-03-10 1998-03-09 Prediccion de la enfermedad arterial coronaria. Expired - Lifetime ES2156843T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US813456 1985-12-26
US08/813,456 US6210877B1 (en) 1997-03-10 1997-03-10 Prediction of coronary artery disease

Publications (2)

Publication Number Publication Date
ES2156843T1 ES2156843T1 (es) 2001-08-01
ES2156843T3 true ES2156843T3 (es) 2008-04-16

Family

ID=25212420

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98910298T Expired - Lifetime ES2156843T3 (es) 1997-03-10 1998-03-09 Prediccion de la enfermedad arterial coronaria.

Country Status (22)

Country Link
US (1) US6210877B1 (enExample)
EP (1) EP0983381B1 (enExample)
JP (2) JP4250765B2 (enExample)
CN (1) CN100523214C (enExample)
AR (1) AR011943A1 (enExample)
AT (1) ATE370246T1 (enExample)
AU (1) AU738875B2 (enExample)
BR (1) BR9808313A (enExample)
CA (1) CA2282746C (enExample)
DE (2) DE69838250T2 (enExample)
DK (1) DK0983381T3 (enExample)
EA (1) EA199900813A1 (enExample)
ES (1) ES2156843T3 (enExample)
GR (1) GR20010300016T1 (enExample)
IL (1) IL131745A0 (enExample)
MX (1) MXPA99008223A (enExample)
NO (1) NO994365L (enExample)
NZ (1) NZ337642A (enExample)
PL (1) PL335603A1 (enExample)
PT (1) PT983381E (enExample)
WO (1) WO1998040517A1 (enExample)
ZA (1) ZA981937B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6524795B1 (en) 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6720141B1 (en) 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
US20050282198A1 (en) * 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
GB9723835D0 (en) * 1997-11-13 1998-01-07 Nicklin Martin Interleukin knockout
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6733967B1 (en) 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
WO1999054707A2 (en) * 1998-04-21 1999-10-28 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
JP2003500005A (ja) * 1999-02-10 2003-01-07 インターリューキン ジェネティックス インコーポレイテッド ＩＬ−１β遺伝子の突然変異に基づく治療および診断
JP2003500069A (ja) * 1999-05-24 2003-01-07 インタールーキン ジェネティックス インク 再狭窄の診断及び治療薬
JP2003508022A (ja) * 1999-06-30 2003-03-04 インターリューキン ジェネティックス インコーポレイテッド Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法
US20030152947A1 (en) * 2001-06-15 2003-08-14 Crossman David C. Methods for detecting and treating the early onset of aging-related conditions
EP1463745A4 (en) * 2001-11-19 2007-11-07 Interleukin Genetics Inc FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 SITE AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
EP1327639A1 (en) * 2002-01-15 2003-07-16 Bayer Ag Prediction of cardiovascular disease by genetic polymorphisms in cardiovascular associated genes
WO2003064600A2 (en) * 2002-01-25 2003-08-07 Interleukin Genetics, Inc. The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
BR0314552A (pt) * 2002-09-30 2005-08-09 Novartis Ag Métodos para prognosticar elevações de colesterol durante terapia imunossupressora
US20050053956A1 (en) * 2002-11-13 2005-03-10 Dietz Harry C. Detection of a predisposition for the development of coronary artery disease
US20060204962A1 (en) * 2003-02-03 2006-09-14 Udo Stropp Genetic polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy
WO2004081186A2 (en) * 2003-03-10 2004-09-23 Applera Corporation Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
CA2566257A1 (en) * 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8105775B2 (en) * 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
RU2310862C1 (ru) * 2006-05-02 2007-11-20 Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ выявления риска развития ишемической болезни сердца
US7935498B2 (en) * 2006-07-07 2011-05-03 Siemens Healthcare Diagnostics Inc. Methods for identifying patients with increased risk of an adverse cardiovascular event
WO2008060627A2 (en) * 2006-11-15 2008-05-22 Interleukin Genetics, Inc. The il-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same
US20090170105A1 (en) * 2007-11-08 2009-07-02 Interleukin Genetics, Inc. Diagnostics for Aging-Related Dermatologic Disorders
US20100112570A1 (en) * 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
CN102747075B (zh) * 2012-06-07 2014-07-23 中国医学科学院阜外心血管病医院 与冠心病相关的6号染色体易感区域标签单核苷酸多态性位点及其组成的单体型与应用
CA3011363A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
CN106202936A (zh) * 2016-07-13 2016-12-07 为朔医学数据科技（北京）有限公司 一种疾病风险预测方法及系统
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
CA3142662A1 (en) 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
CN110277137B (zh) * 2019-06-13 2022-03-18 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种用于检测冠心病的基因芯片信息处理系统及方法
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110920A (en) 1982-01-22 1992-05-05 Cetus Corporation HLA typing method and DNA probes used therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4623619A (en) 1982-03-03 1986-11-18 Nordisk Insulinlaboratorium Method for the determination of liability in human individuals to develop atherosclerosis
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5268267A (en) 1987-08-21 1993-12-07 The General Hospital Corporation Method for diagnosing small cell carcinoma
GB9301453D0 (en) * 1993-01-26 1993-03-17 Clonit Spa Nucleotide proves
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease

Also Published As

Publication number Publication date
JP2009077727A (ja) 2009-04-16
EP0983381A1 (en) 2000-03-08
ES2156843T1 (es) 2001-08-01
EP0983381B1 (en) 2007-08-15
CN100523214C (zh) 2009-08-05
DE69838250T2 (de) 2008-05-08
EA199900813A1 (ru) 2000-06-26
PL335603A1 (en) 2000-05-08
CA2282746A1 (en) 1998-09-17
ATE370246T1 (de) 2007-09-15
US6210877B1 (en) 2001-04-03
JP2001514522A (ja) 2001-09-11
PT983381E (pt) 2007-11-26
CN1255948A (zh) 2000-06-07
WO1998040517A1 (en) 1998-09-17
EP0983381A4 (en) 2004-05-12
AU6457498A (en) 1998-09-29
NO994365D0 (no) 1999-09-09
DK0983381T3 (da) 2007-12-17
NO994365L (no) 1999-11-09
NZ337642A (en) 2001-02-23
DE69838250D1 (de) 2007-09-27
CA2282746C (en) 2009-02-24
MXPA99008223A (es) 2003-07-21
JP4250765B2 (ja) 2009-04-08
AU738875B2 (en) 2001-09-27
IL131745A0 (en) 2001-03-19
DE983381T1 (de) 2000-11-09
ZA981937B (en) 1999-09-06
BR9808313A (pt) 2000-05-16
AR011943A1 (es) 2000-09-13
GR20010300016T1 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
ES2156843T3 (es) Prediccion de la enfermedad arterial coronaria.
Humphries et al. The interleukin-6− 174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men
ES2313894T3 (es) Diagnostico para la enfermedad de placas fragiles.
JP2003506016A (ja) 動脈壁破裂障害のための診断剤および治療剤
US20080118928A1 (en) Diagnostics and therapeutics for arterial wall disruptive disorders
JP2009515557A (ja) 心血管疾患の診断および治療
US5955266A (en) Use of platelet polymorphism P1A2 to diagnose risk of thrombotic disease
Bruikman et al. Genetic variants in SUSD2 are associated with the risk of ischemic heart disease
WO2001091625A2 (en) Methods and compositions for the diagnosis of schizophrenia
KR100976005B1 (ko) 만성 류마티스관절염 질환 감수성 유전자, 이의 단백질,이들을 이용한 만성 류마티스관절염의 발증가능성의 판정방법 및 판정 키트, 및 만성 류마티스관절염의 치료 방법및 치료 약제
US20080268478A1 (en) Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation
LeMaire et al. Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease...
Colonna Identification of High Risk Coronary Artery Disease patient by Molecular Techiniques: the MEF-2A paradigm
CZ9903182A3 (cs) Předpověď onemocnění věnčitých tepen
WO2001087231A2 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001082776A2 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080720A2 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080721A2 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080719A2 (en) Methods and composition for the diagnosis of schizophrenia
GB2433990A (en) Exon 3 mutation of the growth hormone receptor
WO2001082775A2 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001090411A1 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080718A2 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080717A2 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080716A2 (en) Methods and compositions for the diagnosis of schizophrenia